Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

NCT02029001 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

900

Enrollment

OTHER

Sponsor class

Conditions

Malignant Solid Neoplasms

Interventions

DRUG: Nilotinib (400 mg BID)
DRUG: Everolimus (10 mg QD)
DRUG: Sorafenib (400 mg BID)
DRUG: Lapatinib (1500 mg QD)
DRUG: Pazopanib (800 mg QD)
DRUG: Olaparib (300 mg BID)
COMBINATION_PRODUCT: Durvalumab + Tremelimumab

Sponsor

Centre Leon Berard

Collaborators

[object Object]